JP2017518275A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518275A5
JP2017518275A5 JP2016565267A JP2016565267A JP2017518275A5 JP 2017518275 A5 JP2017518275 A5 JP 2017518275A5 JP 2016565267 A JP2016565267 A JP 2016565267A JP 2016565267 A JP2016565267 A JP 2016565267A JP 2017518275 A5 JP2017518275 A5 JP 2017518275A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
aluminum
oxyhydroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565267A
Other languages
English (en)
Japanese (ja)
Other versions
JP6692755B2 (ja
JP2017518275A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/059339 external-priority patent/WO2015165966A1/en
Publication of JP2017518275A publication Critical patent/JP2017518275A/ja
Publication of JP2017518275A5 publication Critical patent/JP2017518275A5/ja
Application granted granted Critical
Publication of JP6692755B2 publication Critical patent/JP6692755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016565267A 2014-04-29 2015-04-29 アルツハイマー病(ad)の処置および予防 Active JP6692755B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166354.2 2014-04-29
EP14166354 2014-04-29
EP14166355.9 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059339 WO2015165966A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (3)

Publication Number Publication Date
JP2017518275A JP2017518275A (ja) 2017-07-06
JP2017518275A5 true JP2017518275A5 (https=) 2018-05-31
JP6692755B2 JP6692755B2 (ja) 2020-05-13

Family

ID=53039896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565267A Active JP6692755B2 (ja) 2014-04-29 2015-04-29 アルツハイマー病(ad)の処置および予防

Country Status (18)

Country Link
US (1) US10478454B2 (https=)
EP (2) EP3137093B1 (https=)
JP (1) JP6692755B2 (https=)
KR (1) KR102388363B1 (https=)
CN (1) CN106659738B (https=)
AU (1) AU2015254663B2 (https=)
CA (1) CA2946928C (https=)
CY (1) CY1119674T1 (https=)
DK (1) DK3137093T3 (https=)
ES (2) ES2824763T3 (https=)
HR (1) HRP20171896T1 (https=)
HU (1) HUE037501T2 (https=)
LT (1) LT3137093T (https=)
NO (1) NO3137093T3 (https=)
PL (1) PL3137093T3 (https=)
PT (1) PT3137093T (https=)
SI (1) SI3137093T1 (https=)
WO (1) WO2015165966A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3137094T3 (pl) * 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
HUP0004331A3 (en) * 1997-08-21 2001-09-28 Gerolymatos P N Sa Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
BR112012024708A2 (pt) * 2010-03-29 2016-06-07 Novartis Ag composição de compostos orgânicos
PL3137094T3 (pl) * 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) * 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)

Similar Documents

Publication Publication Date Title
RU2495662C2 (ru) Антимикробные композиции с контролируемым высвобождением для лечения ушных заболеваний
JP2015526467A5 (https=)
JP2018138578A5 (https=)
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
CN109311832A (zh) 沃替西汀的帕莫酸盐及其晶型
JP2011518119A5 (https=)
JP2012051891A5 (https=)
RU2016119746A (ru) Стабильный состав инсулина глулизин
JP2013513612A5 (https=)
JP2017533972A5 (https=)
JP2016503058A5 (https=)
EP4700016A3 (en) Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
EA201300314A8 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
JP2014515383A (ja) PGF2α類似体を含む眼科用製剤
JP2017518275A5 (https=)
JP2021502379A5 (https=)
JP2019532095A5 (https=)
JP2017514831A5 (https=)
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
JP2017515812A5 (https=)
JP2019507174A5 (https=)
KR20170124322A (ko) 알러지 질환 치료제 전달을 위한 용해성 미세바늘 패치
WO2007092452A2 (en) Formulation and method of use for animal ear treatment and homeopathic animal ear treatment
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
SI3137093T1 (en) Treatment and prevention of Alzheimer's disease